Combining p66Shc inhibitors with ROS‐inducing agents, such as doxorubicin, or targeted therapies, like trastuzumab in HER2‐positive BC, has shown synergistic effects in overcoming resistance [89]. Here, ERBB2 is linked to breast cancer.